Sights for sore eyes and disappointments in psychopharmacology

Klinik Psikofarmakoloji Bulteni

Volumn 24, Issue 2, 2014, Pages 111-114

  Cetin, Mesut ^a   Aricioglu, Feyza ^b  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BITOPERTIN; CHLORPROMAZINE; CLOZAPINE; IPRONIAZID; MINOXIDIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEFAZODONE; NITROPRUSSIDE SODIUM; SULFONAMIDE; THIORIDAZINE;

ANTIDEPRESSANT ACTIVITY; CLINICAL RESEARCH; EDITORIAL; HAIR GROWTH; HISTORY OF MEDICINE; HUMAN; LIVER TOXICITY; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; SLEEP DISORDER; TUBERCULOSIS;

EID: 84904697028     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: 10.5455/bcp.20140626063115     Document Type: Editorial

References (12)

1. Ceylan, ME, Cetin M. (eds) Biological Psychiatry, Schizophrenia, 2005, Yerkure, Istanbul. (Turkish)
2. Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, et al. Effect of bitopertin, a glycine reuptake inhibitor, onnegative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry 2014;71(6):637-646.
3. Goff DC. Bitopertin.The good news and bad news. JAMA Psychiatry 2014;71(6):621-622.
4. Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronicschizophrenia. CNS Drugs 2011;25(10):859-885.
5. Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 2013;263(5):367-377.
6. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007;164(10):1593-1602.
7. Chue P. Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1). Curr Pharm Des 2013;19(7):1311-130.
8. Gruber O, Chadha Santuccione A, Aach H. Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system. Front Psychiatry 2014;5:32.
9. Edgar CJ, Blaettler T, Bugarski-Kirola D, Le Scouiller S, Garibaldi GM, Marder SR. Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms. Psychiatry Res 2014;218(1-2):219-224.
10. Bugarski-Kirola D, Wang A, Abi-Saab D, Blättler T. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - Results from the CandleLyte study. Eur Neuropsychopharmacol 2014;24(7):1024-1036.
11. Hallak JEC, Oliveira JPM, Abrao J, Evora PR, Zuardi AW, Crippa JA, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry 2013;70(7):668-676.
12. Cetin M, Aricioglu F. Unmet needs in psychiatry and emerging novel pharmacological agents. Kli nik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2013;23(3):199-204.